DIRS.INFO The most relevant business & tech news

☆ We have positive momentum in operating performance: Fresenius Medical Care CEO
▼ + stars: | 2024-05-07 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe have positive momentum in operating performance: Fresenius Medical Care CEOHelen Giza, CEO of Fresenius Medical Care, joins CNBC's Annette Weisbach to discuss the company's 2024 first-quarter earnings results.

Persons: Helen Giza, Annette Weisbach Organizations: Fresenius Medical, Fresenius

One strategist, however is looking keenly at European equities, and notes that "Europe isn't a boring market." "You would hope that will translate through to the stock market in terms of company earnings growth in Europe. "While you might see some kind of short-term downturn, in the longer-term the picture is very positive for the sector," Field added. He sees value in payments, which he described as "one of the most undervalued parts of European financial services." The sector has trailed market performance, with valuations looking "interesting" over the last 12 months, Morningstar noted in its recent report.

Persons: Michael Field, Field, Morningstar Organizations: CNBC Pro, European Central Bank, Consumer, Swatch Group, Financial, Morningstar, ING Bank, Group, Health, Novo Nordisk Locations: U.S, Europe, Netherlands, British, Swiss

☆ Fresenius CEO: Taking momentum from reset year and keeping foot on the pedal
▼ + stars: | 2024-02-21 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFresenius CEO: Taking momentum from reset year and keeping foot on the pedalMichael Sen, CEO of Fresenius, lays out how the company has enacted the "reset" pledge he made on CNBC 12 months ago and was able to improve the company's outlook twice in the last year.

Persons: Michael Sen Organizations: CNBC

☆ Fresenius perfectly positioned to combat health inequality, says CEO
▼ + stars: | 2024-01-15 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFresenius perfectly positioned to combat health inequality, says CEOMichael Sen, CEO at Fresenius, explains what the company is doing to help close the health care gap.

Persons: Michael Sen

☆ Corporate America weighs business impact of new weight-loss drugs
▼ + stars: | 2023-11-08 | by ( ) www.reuters.com time to read: +4 min

Walmart (WMT.N) expects revenues from its health and wellness products to increase in the second half of the year, mainly due to the popularity of weight-loss drugs. PepsiCo (PEP.O) Chief Financial Officer Hugh Johnston has said the company is "not seeing any impact" yet from the popularity of weight-loss drugs. Coca-Cola (KO.N) CEO James Quincey said the company was monitoring what impact, if any weight-loss drugs will have. Abbott CEO Robert Ford has said diabetes patients could end up using glucose monitors with the weight-loss drugs in the long term. DRUG DISTRIBUTORSCencora (COR.N), formerly called AmerisourceBergen, Cardinal Health (CAH.N) and McKesson (MCK.N) have flagged potential boost to revenues this year owing to the growing demand for weight-loss drugs.

Persons: Victoria Klesty, Eli Lilly's, Eli Lilly's Zepbound, Hugh Johnston, James Quincey, Michele Buck, Dr Pepper, Robert Gamgort, Johnson, Joseph Wolk, Robert Ford, Michael Farrell, Bhanvi Satija, Ananya Mariam Rajesh, Mrigank Dhaniwala, Arun Koyyur Organizations: REUTERS, U.S . Food, Drug Administration, Walmart, PepsiCo, J, Abbott Laboratories, Insulet Corp, Boston Scientific, Cardinal Health, Thomson Locations: Oslo, Norway, Victoria, U.S, GLP, Bengaluru

☆ Corporate America weighs risks of the Ozempic effect
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: +3 min

Walmart (WMT.N) expects revenues from its health and wellness products to increase in the second half of the year, mainly due to the popularity of weight-loss drugs. PepsiCo (PEP.O) Chief Financial Officer Hugh Johnston has said the company is "not seeing any impact" yet from the popularity of weight-loss drugs. Abbott Laboratories (ABT.N), which makes glucose monitoring products, has said that the market was overestimating the impact to its sales from growing popularity of the drugs. Abbott CEO Robert Ford has said that diabetes patients could end up using glucose monitors with the weight-loss drugs in the long term. DRUG DISTRIBUTORSCencora (COR.N), formerly called AmerisourceBergen, Cardinal Health (CAH.N) and McKesson (MCK.N) have flagged potential boost to revenues this year owing to the growing demand for weight-loss drugs.

Persons: George Frey, Eli Lilly's, Hugh Johnston, Johnson, Joseph Wolk, Robert Ford, Bhanvi, Mrigank Organizations: Novo Nordisk, Pharmacy, REUTERS, Walmart, PepsiCo, Abbott Laboratories, Insulet Corp, Cardinal Health, Thomson Locations: Provo , Utah, U.S, Bengaluru

☆ This highly profitable industry is booming as the population ages
▼ + stars: | 2023-10-15 | by ( Michelle Fox | ) www.cnbc.com time to read: +10 min

Enteral nutrition is administered through a feeding tube or it can be taken orally. Fresenius owns 32% of Fresenius Medical Center, which saw shares drop on recent news that Ozempic's kidney disease treatment trial showed signs of success. Clinical nutrition is about 20% of group profits and an important subset of its larger specialized nutrition unit, Ackerman said. "Many investors only focus only on their infant formula unit and don't know how big or how profitable clinical nutrition is," he said. "Clinical nutrition is the jewel in Danone's crown and probably the most attractive part of Danone's portfolio, yet is hidden from investors."

Persons: Stefano Natella, — hasn't, Hassan Al, Wakeel, Warren Ackerman, Ackerman, Lindsay Clarke, Enteral, Danone's Nutrison, —, Baxter, Abbott, Sara Hennicken, Fresenius, Nestlé, Mark Schneider, Nestle, — CNBC's Michael Bloom Organizations: Guggenheim, World Health Organization, WHO, Barclays, Danone, Fresenius, Al, Alliance for Aging Research, Aging, CNBC, Nestle, Companies, — Nestle, Nutrition, Fresenius Medical Locations: German, Paris, China, Swiss, United States, parenteral, Latin America

☆ Fresenius Medical: effect of drugs like Ozempic on patient numbers is neutral
▼ + stars: | 2023-10-12 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Pens for the diabetes drug Ozempic sit on a production line at Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. "Based on currently available clinical data and scientific evidence, Fresenius Medical Care assesses the overall effect of GLP-1 analog use on its own patient flow model as neutral," it said in a statement to Reuters. Novo said on Wednesday that the Ozempic trial was stopped ahead of schedule because independent supervisors had ruled the drug's positive effect on chronic kidney disease had become clear enough. In its statement, Fresenius Medical said that the early termination of the study, known as FLOW, does not allow for clear conclusions. Earlier on Thursday, rival DaVita (DVA.N) said that Novo's FLOW trial would only have a limited impact on overall dialysis patient numbers.

Persons: Tom Little, DaVita, Novo, Fresenius, Ludwig Burger, Jane Merriman, Kirsten Donovan Organizations: REUTERS, Rights, Novo Nordisk's, Reuters, Thomson Locations: Hillerod, Denmark

☆ Luxury stocks drag European shares lower on LVMH disappointment
▼ + stars: | 2023-10-11 | by ( ) www.reuters.com time to read: +1 min

The logo of LVMH is seen at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France, June 15, 2023. REUTERS/Gonzalo Fuentes/File photo Acquire Licensing RightsOct 11 (Reuters) - European stocks slipped on Wednesday after sharp gains in the previous session, as luxury giant LVMH dragged the sector lower on disappointing sales, though Novo Nordisk jumped after positive update on its diabetes drug Ozempic. The pan-European STOXX 600 index (.STOXX) dipped 0.2% by 0707 GMT. Shares of other French luxury majors such as Hermes (HRMS.PA) and Kering (PRTP.PA) fell 2.5% and 2.7%, respectively. Swiss luxury firms Richemont (CFR.S) fell 5.3% and Swatch Group (UHR.S) dropped 2.9%.

Persons: Gonzalo Fuentes, Danish drugmaker, Sruthi Shankar, Rashmi Organizations: Viva Technology, Porte de, REUTERS, Novo Nordisk, U.S . Federal Reserve, Swatch Group, Fresenius, Thomson Locations: Porte, Paris, France, U.S, Danish, Bengaluru

☆ Obesity revolution gorges on dialysis maker
▼ + stars: | 2023-10-11 | by ( Aimee Donnellan | ) www.reuters.com time to read: +3 min

REUTERS/Megan Jelinger Acquire Licensing RightsLONDON, Oct 11 (Reuters Breakingviews) - Kidney dialysis kit-makers look set to be the latest victim of the obesity drug boom. On Wednesday, shares in Germany-listed Fresenius Medical Care (FMEG.DE) fell 20% after a medical trial showed a Novo Nordisk (NOVOb.CO) drug can reduce the risk of kidney failure. Diabetes and obesity drugs are showing their fringe benefits. In a recent drug trial, Wegovy, an obesity remedy made by Denmark’s Novo Nordisk, reduced the incidence of serious cardiovascular events like strokes and heart attacks by 20% in overweight patients. The collapse in Fresenius Medical Care’s share price looks appropriate.

Persons: Dawn, Megan Jelinger, Michael Sen, Danish drugmaker, Neil Unmack, Oliver Taslic Organizations: REUTERS, Reuters, Novo Nordisk, Denmark’s Novo Nordisk, Fresenius, Thomson Locations: Findlay , Ohio, U.S, Germany, Fresenius, Vamed, Danish

☆ Shares of dialysis providers drop after Ozempic's early kidney trial success
▼ + stars: | 2023-10-11 | by ( ) www.reuters.com time to read: +2 min

The outdoor sign seen at the DaVita Dialysis clinic in Denver February 16, 2016. U.S.-listed shares of Fresenius fell 16.4%, to $17.5, and Davita fell about 16%, to $76.7, in premarket hours. Shares of U.S.-based Baxter International (BAX.N), which makes products used by dialysis therapy providers, also fell about 9%, to $33.99 premarket. Davita and U.S.-listed shares of Fresenius Medical are among the top percentage losers on the New York Stock Exchange. As of Tuesday's close, U.S.-listed shares of Fresenius were up about 28.2%, Davita's shares were up 22.2%, while Baxter's shares were down about 27% so far this year.

Persons: Rick Wilking, Ozempic, Danish drugmaker, Veronika Dubajova, Davita, Eli Lilly's, Akash Tewari, Fresenius, Mariam Sunny, Janane Venkatraman, Pooja Desai Organizations: REUTERS, Novo Nordisk's, Citi, Baxter, Jefferies, Fresenius, New York Stock Exchange ., Thomson Locations: Denver, Danish, Fresenius, New York Stock Exchange . Frankfurt, U.S, Bengaluru

☆ Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon Mobil, Amgen and more
▼ + stars: | 2023-10-11 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Novo Nordisk — The Danish drugmaker stock added 5.5% after saying late Tuesday it was halting Ozempic's kidney disease treatment trial after a committee said an analysis showed signs of success. DaVita , Fresenius Medical Care , Baxter International — Shares of dialysis services providers DaVita and Fresenius Medical Care sank 18.4% and 19.6%, respectively, on Novo Nordisk's news. Exxon Mobil , Pioneer Natural Resources — Exxon Mobil shares fell more than 4% after the largest U.S. oil and gas producer agreed to buy shale rival Pioneer Natural Resources for $59.5 billion in an all-stock deal, or $253 per share. Amgen — The biopharma stock added 3.5% following an upgrade from Leerink to outperform. On Wednesday, B. Riley upgraded shares to buy from neutral, saying Coherent's silicon carbide business could be worth more than the Street's current estimate.

Persons: Eli Lilly, Bruce Broussard, Jim Rechtin, Amgen, David Risinger, Goldman Sachs, Jeffrey Brown, Tim Wentworth, Riley, Raymond James, — CNBC's Michael Bloom, Hakyung Kim, Yun Li, Lisa Han Organizations: Novo Nordisk, Novo Nordisk —, Baxter, Fresenius, Novo Nordisk's, Baxter International, Exxon Mobil, Natural Resources, Exxon, Exxon's, Mobil, Healthcare, Goldman, Walgreens, Alliance Locations: Danish, Novo

Healthcare workers strike in front of Kaiser Permanente Los Angeles Medical Center, as more than 75,000 Kaiser Permanente healthcare workers go on strike from October 4 to 7 across the United States, in Los Angeles, California, U.S. October 4, 2023. WHAT ARE KAISER WORKERS' DEMANDS AND WHAT IS THE COMPANY OFFERING? Some of the key demands by the workers include higher pay to keep up with the cost of living, a $25-per-hour minimum wage for all healthcare workers, and a reformed bonus structure. The union insists Kaiser needs to hire 10,000 new healthcare workers to fill current vacancies, as well as "fix broken hiring processes" that are preventing full staffing. The unions are asking Kaiser Permanente to make massive investment in the education and training of future healthcare workers, and for a diminished role for vendors and third-party contractors that the healthcare network relies on.

Persons: Julie Su, Kaiser, Kaiser Permanente, John August, Russ Richmond, Leroy Leo, Bhanvi, Ahmed Aboulenein, Steve Gorman, Shinjini Ganguli, Diane Craft Organizations: Kaiser Permanente Los Angeles Medical Center, Permanente, REUTERS, Kaiser Permanente, Labor, AMN Healthcare, District of Columbia, Cornell's School of Industrial and Labor Relations, Tenet Healthcare, Satellite Healthcare, Fresenius, Thomson Locations: United States, Los Angeles , California, U.S, Kaiser, California, Bengaluru, Washington, Los Angeles

☆ KKR in talks to buy Spanish fertility clinic company Eugin from Fresenius -report
▼ + stars: | 2023-10-02 | by ( ) www.reuters.com time to read: +1 min

[1/2] General view of the Fresenius SE logo on the company's headquarters in Bad Homburg near Frankfurt, Germany, February 25, 2015. REUTERS/Ralph Orlowski/File Photo/File Photo Acquire Licensing RightsMADRID, Oct 2 (Reuters) - United States-based buyout fund KKR (KKR.N) is in exclusive talks with Germany' Fresenius (FREG.DE) to buy Eugin, fertility clinics in Spain and Portugal, Spanish newspaper Cinco Dias reported on Monday citing unidentified financial sources. A potential deal would value Eugin at around 500 million euros ($528.55 million), the newspaper said. The U.S. fund already owns assets in the industry in the country, Cinco Dias reported. KKR, Fresenius and Eugin did not immediately respond to messages seeking comment.

Persons: Ralph Orlowski, Cinco Dias, Eugin, Inti Landauro, Louise Heavens Organizations: REUTERS, Rights, KKR, Fresenius, Thomson Locations: Bad Homburg, Frankfurt, Germany, Rights MADRID, United States, Spain, Portugal, Spanish, U.S

☆ Fresenius to assess whether state aid impacts bonus, dividend payouts
▼ + stars: | 2023-09-30 | by ( ) www.reuters.com time to read: +2 min

Companies Fresenius SE & Co KGaA FollowFRANKFURT, Sept 30 (Reuters) - German healthcare group Fresenius (FREG.DE) said it was examining whether the state aid it received to help offset high energy costs at its hospitals business would bar it from making management bonus and dividend payments. When asked whether the company would legally challenge any ban on payouts, he said that would have to be analysed. The company paid an unchanged annual dividend of 0.92 euros a share this year, or 518 million euros in total. The spokesperson said the assessment would inform a decision on whether state aid will be accepted during the second half. The Helios unit posted earnings before interest and tax of 622 million euros in the first half against 609 million a year earlier.

Persons: Michael Sen, Sen, Helios, Ludwig Burger, Jan Harvey Organizations: Frankfurter Allgemeine, Reuters, Helios, Thomson Locations: FRANKFURT

☆ Shares in Pfizer rivals Hikma, Fresenius rally after tornado hits factory
▼ + stars: | 2023-07-20 | by ( Lucy Raitano | ) www.reuters.com time to read: +1 min

Hikma shares rose by as much as 9.4% in their largest one-day increase since last September. Pfizer is the largest supplier in the U.S. injectables market and Hikma is the second-largest, analysts said. Hikma, which has a market value of around $5.6 billion compared with Pfizer's $205.7 billion, might struggle to meet demand, Herrmann said. European healthcare stocks (.SXDP) were up around 0.7% on the day, outperforming the broader STOXX 600 (.STOXX), which rose 0.4%. Pfizer shares were up 0.16% in premarket trading.

Persons: Fresenius, Max Herrmann, Herrmann, Hikma, Amanda Cooper, Jan Harvey Organizations: Pfizer, Reuters, Thomson Locations: U.S, Rocky Mount, North Carolina, Hikma

☆ Hikma, Fresenius shares rally after tornado hits rival Pfizer's U.S. plant
▼ + stars: | 2023-07-20 | by ( Lucy Raitano | ) www.reuters.com time to read: +2 min

Nearly 25 percent of all sterile injectables used in U.S. hospitals are produced at the Rocky Mount facility, according to Pfizer's website. Hikma shares rose by as much as 9.4% in their largest one-day increase since last September, hitting an 18-month high. Pfizer is the largest supplier in the U.S. injectables market and Hikma is the second-largest, analysts said. Hikma has a market value of around $5.6 billion, compared with Pfizer's $205.7 billion and Fresenius SE's $16.7 billion, according to Refinitiv data. Pfizer shares were up 0.16% in premarket trading.

Persons: Fresenius, Max Herrmann, Herrmann, Hikma, J.P.Morgan, Amanda Cooper, Jan Harvey, Mike Harrison Organizations: Pfizer, Rocky, U.S . Food, Drug Administration, Thomson Locations: U.S, Rocky Mount, North Carolina, Hikma

The pan-European STOXX 600 index (.STOXX) closed 0.1% higher, snapping its six-day losing streak. "Markets are expecting either the data to improve from China or stimulus to increase from the government. "This realization is dawning among investors yet again, that the inflationary fight is far from over." The healthcare sector has been declining in recent weeks and is down nearly 2.9% so far this month. Reporting by Amruta Khandekar, Siddarth S and Matteo Allievi in Gdansk; Editing by Rashmi Aich, Sonia Cheema, William MacleanOur Standards: The Thomson Reuters Trust Principles.

Persons: ECB's Lagarde, Christine Lagarde, Li Qiang, Giles Coghlan, Susannah Streeter, Hargreaves Lansdown, Streeter, Goldman Sachs, Amruta Khandekar, Siddarth, Matteo Allievi, Rashmi Aich, Sonia Cheema, William Maclean Organizations: European Central Bank, HSBC, Prudential Plc, Hargreaves, Siemens Energy, Thomson Locations: China, Russia, U.S, Gdansk

☆ U.S. seeks new suppliers of highly used cancer drug methotrexate in short supply
▼ + stars: | 2023-06-09 | by ( ) www.cnbc.com time to read: +2 min

The U.S. Food and Drug Administration said on Friday it is seeking new suppliers to ease shortages of methotrexate, one of the most commonly used cancer drugs, building on its push to shore up two other scarce chemotherapy medicines. An FDA spokesperson told Reuters the agency is looking for temporary importation options for the drug, which has been in shortage since March. Methotrexate is an injected drug used to treat a wide variety of cancers ranging from acute lymphoblastic leukemia in children, breast cancer, lung cancer, bone cancers and certain types of head and neck cancers, according to the National Cancer Institute. Last week, the FDA said it was looking for additional temporary suppliers for two other cancer chemotherapies, cisplatin and carboplatin. According to the American Society of Health-System Pharmacists, suppliers with methotrexate injections in shortage or on back order include Accord Healthcare, Fresenius Kabi, Pfizer , Teva and Hikma Pharmaceuticals .

Persons: Methotrexate, cisplatin, China's, Senators Gary Peters, Debbie Stabenow, Fresenius Kabi Organizations: . Food, Drug Administration, FDA, Reuters, National Cancer Institute, Pharmaceutical, U.S, Senators, Intas Pharmaceuticals, Healthcare, American Society of Health, System Pharmacists, Accord Healthcare, Pfizer, Teva, Hikma Pharmaceuticals Locations: United States, India, U.S

☆ CVS and NEA just sank $166 million into a startup building a new care model for kidney disease. Here's the pitch deck that convinced CapitalG to back Strive Health's Series B.
▼ + stars: | 2023-06-07 | by ( Lydia Ramsey Pflanzer | Megan Hernbroth | Rebecca Torrence | ) www.businessinsider.com time to read: +3 min

Strive Health just raised $166 million in May from investors like NEA and CVS Health Ventures. See the presentation that got Strive Health a $140 million Series B in March 2021. In May, Strive Health announced it raised $166 million in Series C funding led by healthcare venture firm NEA. The round included CVS Health Ventures, CapitalG, Echo Health Ventures, Town Hall Ventures, Ascension Ventures, and Redpoint. The Series C is Strive Health's latest raise since its $140 million Series B in March 2021.

Persons: Chris Riopelle, Riopelle Organizations: NEA, CVS Health Ventures, Health, Echo Health Ventures, Hall Ventures, Ascension Ventures, CapitalG, Google

☆ A top healthcare banker names the 4 industry sectors ripe for M&A
▼ + stars: | 2023-05-10 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +2 min

Pearson said that she expects to see more deals in women's health, orthopedics, cardiology, and kidney care, areas that remain largely unconsolidated today. She worked with Unified Women's Healthcare in its 2020 deal with Altas Partners and Ares Management. Last year, Unified Women's Healthcare acquired digital menopause provider platform Gennev. While some companies in these sectors are making deals to obtain more digital capabilities, others are investing internally in virtual capabilities. Kidney-care-focused companies U.S. Renal Care and DaVita are also investing in their virtual capabilities, she added.

☆ Fresenius Medical's operating profit drops less than feared as labour shortages ease
▼ + stars: | 2023-05-09 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

FRANKFURT, May 9 (Reuters) - Fresenius Medical Care (FMEG.DE) said on Tuesday labour shortages were slowly easing as the German dialysis specialist reported a drop in its first-quarter adjusted operating income, although not as steep as feared by some analysts. The company said in a statement on Tuesday its adjusted operating income dropped to 354 million euros ($390 million), compared with the median analysts' estimate of 335 million in a consensus posted on the company's website. The dialysis group's parent Fresenius SE (FREG.DE) has said this year it would cede control over the struggling dialysis firm, but keep its stake for now as part of a turnaround plan. Fresenius Medical, which was hit hard by a high rate of COVID-19 deaths among its patients, said this burden was easing, though excess mortality for now continued to weigh on growth. Its parent company, German healthcare group Fresenius (FREG.DE), said on Tuesday its first-quarter operating earnings slipped a currency-adjusted 10%.

☆ 'A hidden gem': Barclays names 3 stocks to buy in an overlooked area of health care
▼ + stars: | 2023-04-14 | by ( Weizhen Tan | ) www.cnbc.com time to read: +3 min

There's a global investing opportunity in a corner of health care that is both "significant and underappreciated," according to Barclays. For Nestle, that shift is also a catalyst for more growth in China as the market expands, the bank said. "We view it as a 'hidden jewel' where we expect increased investment from the new management team," Barclays said. German health care company Fresenius is also a "clear beneficiary" of the shift toward enteral nutrition, as it's set to leverage its leadership position in China in that area, the bank said. It also has a strong position in enteral in the region, positioning it to benefit from the high potential for growth."

☆ Blackstone and Bumble are still a fitting match
▼ + stars: | 2023-02-23 | by ( ) www.reuters.com time to read: +2 min

NEW YORK, Feb 23 (Reuters Breakingviews) - Blackstone (BX.N) is finding its pairing with Bumble (BMBL.O) to be lucrative even during a down spell. The private equity firm bought a majority stake in Bumble in 2019 that valued the company at around $3 billion. The share of stock that Blackstone sold in the public offering inked it almost $2 billion. Throw in approximately $300 million in dividends, and Blackstone has already made back its investment and then some. The match is winning enough that Blackstone is raising more money to find others to share the love.

☆ Miners’ bets on the future of coal are diverging
▼ + stars: | 2023-02-23 | by ( ) www.reuters.com time to read: +2 min

LONDON, Feb 23 (Reuters Breakingviews) - Investors have a common understanding that coal is the dirtiest energy source. UK-listed Anglo American’s (AAL.L) earnings on Thursday showed EBITDA in the $50 billion group’s metallurgical coal division tripled to over $2.7 billion in 2022. With “met coal” constituting a fifth of Anglo’s overall EBITDA, investors may wonder whether boss Duncan Wanblad will follow Teck’s step. That’s probably because even though met coal generates three times more carbon than thermal coal, used to generate electricity, it’s still expensive to produce steel at scale in a sustainable way without using a coal-guzzling blast furnace. Anglo’s experiences hiving off its own thermal coal business, meanwhile, may not encourage Wanblad to repeat the trick.

Search resuls for: "Fresenius"

25 mentions found